Boston Scientific Profit Falls Even as Demand for Its Heart Products Surges

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of the most notable news stories of the time.

Erica Denhoff / Icon Sportswire via Getty Images

Boston Scientific (BSX) shares fell Wednesday when the medical equipment manufacturer's third-quarter profit fell and its GAAP earnings per share (EPS) came in short of its guidance.

The company reported net income declined 7% year-over-year to $469 million, below the $543 million consensus estimate of analysts surveyed by Visible Alpha. EPS came in a penny below expectations at $0.32, while Boston Scientific had predicted a range of $0.36 to $0.38. Adjusted EPS of $0.63 was better than projections and the company's prior guidance.

Revenue surged 19% to $4.21 billion, above forecasts, boosted by a 25% sales jump of its cardiovascular products to $2.73 billion. The MedSurg division, which includes endoscopy, urology, and neuromodulation devices, had a 10% revenue rise to $1.48 billion.

The company now sees full-year EPS to be in a range of $1.28 to $1.30, down from its previous outlook of $1.34 to $1.38. However, it anticipates adjusted EPS to be $2.45 to $2.47, exceeding the earlier $2.38 to $2.42. It predicts net sales growth of 16.5%, ahead of its prior estimate of 13.5% to 14.5%.

Shares of Boston Scientific hit a record intraday high Monday, and even with today's 2.5% decline they're still up nearly 50% year-to-date.

TradingView

Boston Scientific. "Boston Scientific Announces Results for Third Quarter 2024."

Boston Scientific. "Boston Scientific Announces Results for Second Quarter 2024."